Our Current Partnerships include:
In Dec 2015, we signed worldwide license agreement with Roche for a VAP-1 inhibitor discovered by the team at Proximagen and moved into Phase II development. Proximagen are collaborating with Roche to conduct further Phase II trials on this molecule.
In January 2016, we entered a research collaboration with Saniona to identify candidate drugs acting on an ion channel drug target implicated in pain and other neurological disorders. Proximagen is responsible for development of candidate drugs arising from the collaboration and Saniona is entitled to downstream development milestones and royalties on any resulting products.